Global Fund on malaria treatments...
Over the past few months, there has been a lively debate about the need to respond to the widespread and increasing resistance to available malaria drugs and thereby to accelerate our combined efforts to Roll Back Malaria. The Global Fund, as the world’s largest financier of malaria programs, must play an important role in this effort.
The Global Fund has rapidly become the main financial engine behind the scale-up of artemisinin-based combination therapies (ACT). We recognize the need to take a more proactive role in facilitating the change to ACT, where data suggest that existing drugs are ineffective.
The Global Fund has committed to a set of actions (some completed, some ongoing, some newly initiated) in order to play its full part in the accelerated use of effective malaria treatment. Together, these steps are aimed at ensuring that the Global Fund will encourage and facilitate a rapid shift to ACT where appropriate, both in already approved and future grants. See Global Fund commitments (PDF - 11 Kb) and outline of Global Fund malaria treatment review process (PDF - 9 Kb).
An article in January this year (Attaran et al, “Viewpoint: WHO, the Global Fund, and medical malpractice in malaria treatment”, The Lancet, Vol 363, January 17, 2004 has been central to the ongoing debate. The Global Fund fully supports The Lancet article’s authors in calling for a more rapid change to effective malaria treatment, and we acknowledge the article’s importance in bringing the proper urgency to the issue.
 The Lancet website
| |
 |
|
| The Global Fund's response (PDF - 13 Kb) |
|
|
|
| Misrepresentations and Inaccuracies in the Lancet article (PDF - 15 Kb) |
|
|
|
| CCM explanatory letter (PDF - 12 Kb) |
|
|
|
| The Global Fund’s latest response to the Lancet exchange (PDF - 10 Kb) |
|
